Androgen excess and diagnostic steroid biomarkers for nonclassic 21-hydroxylase deficiency without cosyntropin stimulation
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The clinical presentation of patients with nonclassic 21-hydroxylase deficiency (N21OHD) is similar with that for other disorders of androgen excess. The diagnosis of N21OHD typically requires cosyntropin stimulation. Additionally, the management of such patients is limited by the lack of reliable biomarkers of androgen excess. Herein, we aimed to: (1.) compare the relative contribution of traditional and 11-oxyandrogens in N21OHD patients and (2.) identify steroids that accurately diagnose N21OHD with a single baseline blood draw. DESIGN: We prospectively enrolled patients who underwent a cosyntropin stimulation test for suspected N21OHD in two tertiary referral centers between January 2016 and August 2019. METHODS: Baseline sera were used to quantify 15 steroids by liquid chromatography-tandem mass spectrometry. Logistic regression modeling was implemented to select steroids that best discriminate N21OHD from controls. RESULTS: Of 86 participants (72 females), median age 26, 32 patients (25 females) had N21OHD. Age, sex distribution, and BMI were similar between patients with N21OHD and controls. Both testosterone and androstenedione were similar in patients with N21OHD and controls, while four 11-oxyandrogens were significantly higher in patients with N21OHD (ratios between medians: 1.7 to 2.2, P < 0.01 for all). 17α-Hydroxyprogesterone (6.5-fold), 16α-hydroxyprogesterone (4.1-fold), and 21-deoxycortisol (undetectable in 80% of the controls) were higher, while corticosterone was 3.6-fold lower in patients with N21OHD than in controls (P < 0.001). Together, baseline 17α-hydroxyprogesterone, 21-deoxycortisol, and corticosterone showed perfect discrimination between N21OHD and controls. CONCLUSIONS: Adrenal 11-oxyandrogens are disproportionately elevated compared to conventional androgens in N21OHD. Steroid panels can accurately diagnose N21OHD in unstimulated blood tests.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“11-oxyandrogens are the major androgens and androgen precursors found in classic and nonclassic 21OHD (12, 16)”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In particular, a set of 11-oxygenated-C19 steroids (11-oxyandrogens), including 11β-hydroxyandrostenedione (11OHA4) and 11-ketotestosterone (11KT), have been shown to be elevated in patients with classic (12, 15) and non-classic 21OHD (16).”
From 24-Hour Profiles of 11-Oxygenated C19 Steroids and Δ5-Steroid Sulfates during Oral and Continuous Subcutaneous Glucocorticoids in 21-Hydroxylase Deficiency (2021) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In contrast to DHEAS, androstenedione and testosterone, 11KT does not decline with age in women from 20 to 80-years old, and 11KT declines very gradually in men over the same age range (130).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [130]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Congenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationGenotyping steroid 21-hydroxylase deficiency: hormonal reference data
NEW, M. I., LORENZEN, F., LERNER, A. J., KOHN, B., OBERFIELD, S. E., POLLACK, M. S., DUPONT, B., STONER, E., LEVY, D. J., PANG, S., et al. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-2-320 · Cited by 624
Therrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344 · cited 1×
“Patients with classic 21OHD have marked 17OHP4 elevations in random samples and are typically diagnosed by newborn screening in most developed countries (6).”
BackgroundSteroid 21-hydroxylase deficiency: genotype may not predict phenotype
Wilson, R. C. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.8.2322 · Cited by 324
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome
O’Reilly, M. W., Kempegowda, P., Jenkinson, C., Taylor, A. E., Quanson, J. L., Storbeck, K.-H., & Arlt, W. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3285 · Cited by 267
Azziz, R., Hincapie, L. A., Knochenhauer, E. S., Dewailly, D., Fox, L., & Boots, L. R. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00383-0 · Cited by 244
Turcu, A. F., Nanba, A. T., Chomic, R., Upadhyay, S. K., Giordano, T. J., Shields, J. J., Merke, D. P., Rainey, W. E., & Auchus, R. J. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1181 · Cited by 231 · cited 2×
“androgen 11-ketotestosterone (11KT) and the other 11-oxygenated C19 steroids (11oxyandrogens) are elevated in patients with classic 21OHD (22, 23).”
BackgroundSelf-citationBidet, M., Bellanné-Chantelot, C., Galand-Portier, M.-B., Tardy, V., Billaud, L., Laborde, K., Coussieu, C., Morel, Y., Vaury, C., Golmard, J.-L., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1582 · Cited by 213
Janzen, N., Peter, M., Sander, S., Steuerwald, U., Terhardt, M., Holtkamp, U., & Sander, J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2890 · Cited by 211 · cited 1×
“Compared to conventional newborn screening using immunoassay-based 17OHP4 alone, LC-MS/MS testing for simultaneous elevations of 21dF and 17OHP4 plus low cortisol was shown to reduce false-positive results (30).”
ResultCarmina, E., Dewailly, D., Escobar-Morreale, H. F., Kelestimur, F., Moran, C., Oberfield, S., Witchel, S. F., & Azziz, R. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx014 · Cited by 201 · cited 1×
“To further complicate the clinical assessment, polycystic ovarian morphology is common in women with nonclassic 21OHD (5).”
BackgroundStorbeck, K.-H., Bloem, L. M., Africander, D., Schloms, L., Swart, P., & Swart, A. C. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.07.006 · Cited by 198
Casteràs, A., De Silva, P., Rumsby, G., & Conway, G. S. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03563.x · Cited by 190
Moran, C., Azziz, R., Carmina, E., Dewailly, D., Fruzzetti, F., Ibañez, L., Knochenhauer, E. S., Marcondes, J. A. M., Mendonca, B. B., Pignatelli, D., et al. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.108020 · Cited by 185
Wong, T., Shackleton, C. H., Covey, T. R., & Ellis, G. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.9.1830 · Cited by 159 · cited 1×
“Since the 1960s, steroids have been measured by immunoassays, which are limited by crossreactivity and can yield unreliable results, particularly near the limits of sensitivity and in the presence of high concentrations of similar steroids (27, 28).”
BackgroundMinutti, C. Z., Lacey, J. M., Magera, M. J., Hahn, S. H., McCann, M., Schulze, A., Cheillan, D., Dorche, C., Chace, D. H., Lymp, J. F., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032235 · Cited by 154 · cited 1×
“Since the 1960s, steroids have been measured by immunoassays, which are limited by crossreactivity and can yield unreliable results, particularly near the limits of sensitivity and in the presence of high concentrations of similar steroids (27, 28).”
BackgroundRege, J., Turcu, A., Kasa-Vubu, J. Z., Lerario, A. M., Auchus, G. C., Auchus, R. J., Smith, J. M., White, P. C., & Rainey, W. E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00736 · Cited by 154 · cited 1×
“11KT is recognized as a potent androgen of adrenal origin in human beings (35–37), which mediates clinical manifestations of normal and premature adrenarche (35) and correlates well with clinical surrogates of poor disease control in patients with classic 21OHD (24).”
BackgroundSelf-citationPretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159867 · Cited by 148
Armengaud, J.-B., Charkaluk, M.-L., Trivin, C., Tardy, V., Bréart, G., Brauner, R., & Chalumeau, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0314 · Cited by 135 · cited 1×
“Although T and A4 elevations have been reported in children with nonclassic 21OHD (34), these androgens have been more inconsistent in adults with nonclassic 21OHD.”
BackgroundStructural Insights into Aldosterone Synthase Substrate Specificity and Targeted Inhibition
Strushkevich, N., Gilep, A. A., Shen, L., Arrowsmith, C. H., Edwards, A. M., Usanov, S. A., & Park, H.-W. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1287 · Cited by 135 · cited 1×
“Similarly, 11βhydroxylase (CYP11B1) can also utilize as substrates androstenedione (A4) and testosterone (T), leading to ample amounts of 11β-hydroxyandrostenedione (11OHA4) and 11βhydroxytestosterone (11OHT), respectively (20, 21).”
BackgroundOlgemöller, B., Roscher, A. A., Liebl, B., & Fingerhut, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021732 · Cited by 124
Janzen, N., Sander, S., Terhardt, M., Peter, M., & Sander, J. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.11.006 · Cited by 119
11-oxygenated C19 steroids Do not decline with age in women
Nanba, A. T., Rege, J., Ren, J., Auchus, R. J., Rainey, W. E., & Turcu, A. F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02527 · Cited by 113 · cited 1×
“Steroid quantitation by mass spectrometry Quantitation of 15 unconjugated Δ4 steroids, including cortisol precursors, T4, A4 and four 11-oxyandrogens, from sera obtained at baseline was performed by LC-MS/MS, as previously described (26).”
MethodTurcu, A. F., Mallappa, A., Elman, M. S., Avila, N. A., Marko, J., Rao, H., Tsodikov, A., Auchus, R. J., & Merke, D. P. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3989 · Cited by 107 · cited 2×
“11KT is recognized as a potent androgen of adrenal origin in human beings (35–37), which mediates clinical manifestations of normal and premature adrenarche (35) and correlates well with clinical surrogates of poor disease control in patients with classic 21OHD (24).”
BackgroundSelf-citationSchwarz, E., Liu, A., Randall, H., Haslip, C., Keune, F., Murray, M., Longo, N., & Pasquali, M. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181aa3777 · Cited by 97
Nordenström, A., Wedell, A., Hagenfeldt, L., Marcus, C., & Larsson, A. (2001) · Pediatrics · doi:10.1542/peds.108.4.e68 · Cited by 93
Congenital adrenal hyperplasia: time to replace 17OHP with 21-deoxycortisol
Miller, W. L. (2019) · Hormone Research in Paediatrics · doi:10.1159/000501396 · Cited by 93
Profiles of 21-Carbon Steroids in 21-Hydroxylase Deficiency
Turcu, A. F., Rege, J., Chomic, R., Liu, J., Nishimoto, H. K., Else, T., Moraitis, A. G., Palapattu, G. S., Rainey, W. E., & Auchus, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1023 · Cited by 77 · cited 2×
“In addition to 17OHP4, we found that 16OHP4 and 21dF are also significantly higher in patients with nonclassic 21OHD than in unaffected individuals, albeit lower than previously shown in patients with classic 21OHD (16).”
BackgroundResultKamrath, C., Wettstaedt, L., Boettcher, C., Hartmann, M. F., & Wudy, S. A. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.12.016 · Cited by 71 · cited 1×
“androgen 11-ketotestosterone (11KT) and the other 11-oxygenated C19 steroids (11oxyandrogens) are elevated in patients with classic 21OHD (22, 23).”
Background11β-Hydroxyandrostenedione Returns to the Steroid Arena: Biosynthesis, Metabolism and Function
Bloem, L., Storbeck, K.-H., Schloms, L., & Swart, A. (2013) · Molecules · doi:10.3390/molecules181113228 · Cited by 60
Costa‐Barbosa, F. A., Tonetto‐Fernandes, V. F., Carvalho, V. M., Nakamura, O. H., Moura, V., Bachega, T. A. S. S., Vieira, J. G. H., & Kater, C. E. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03871.x · Cited by 50 · cited 1×
“Extended to larger populations, similar steroid panels could potentially differentiate between classic, nonclassic, carriers of 21OHD and healthy individuals in single baseline samples, as was previously proposed with cosyntropin stimulation (17, 18).”
BackgroundCavarzere, P., Samara-Boustani, D., Flechtner, I., Dechaux, M., Elie, C., Tardy, V., Morel, Y., & Polak, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0145 · Cited by 41
Costa‐Barbosa, F. A., Carvalho, V. M., Nakamura, O. H., Bachega, T. A. S. S., Vieira, J. G. H., & Kater, C. E. (2011) · PubMed · doi:10.3275/7273 · Cited by 20 · cited 1×
“Extended to larger populations, similar steroid panels could potentially differentiate between classic, nonclassic, carriers of 21OHD and healthy individuals in single baseline samples, as was previously proposed with cosyntropin stimulation (17, 18).”
BackgroundReplication of clinical associations with 17-hydroxyprogesterone in preterm newborns
Ryckman, K. K., Cook, D. E., Berberich, S. L., Shchelochkov, O. A., Berends, S. K., Busch, T. D., Dagle, J. M., & Murray, J. C. (2012) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2011-0456 · Cited by 20
Pauwels, G., Allegaert, K., Régal, L., & Meulemans, A. (2012) · PubMed · doi:10.2143/acb.67.2.2062637 · Cited by 6
Milewicz, A., Vecsei, P., Gruszka, S., Szymczak, J., Bednarek-Tupikowska, G., & Grabiński, M. (1984) · PubMed · Cited by 3
Cited by
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Nonclassic Congenital Adrenal Hyperplasia
Jha, S., & Turcu, A. F. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.008 · Cited by 64
Sarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Steroid reference intervals in women: influence of menopause, age and metabolism
Mezzullo, M., Gambineri, A., Dalmazi, G. D., Fazzini, A., Magagnoli, M., Baccini, M., Vicennati, V., Pelusi, C., Pagotto, U., & Fanelli, F. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1147 · Cited by 28
Production of 11-Oxygenated Androgens by Testicular Adrenal Rest Tumors
Schröder, M. A. M., Turcu, A. F., O’Day, P., van Herwaarden, A. E., Span, P. N., Auchus, R. J., Sweep, F. C. G. J., & der Grinten, H. L. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab598 · Cited by 24
Metadata
- Authors
- Turcu, A. F., El-Maouche, D., Zhao, L., Nanba, A. T., Gaynor, A., Veeraraghavan, P., Auchus, R. J., & Merke, D. P.
- Affiliations
- University of Michigan (US)
- 2National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA
- National Institutes of Health (US)
- Corresponding author
- Turcu, Adina F
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-07
- Volume
- 183
- Issue
- 1
- Pages
- 63-71
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- PMC
- PMC7458124
- OpenAlex
- W3022960885
- Cited by
- 33
- References
- 41
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 11
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM086596)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK109116)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- hyperandrogenism, steroid biomarkers, 17-hydroxyprogesterone, 21-deoxycortisol, corticosterone, 16α-hydroxyprogesterone, ACTH stimulation test
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Adult, Aged, Androgens, Child, Cosyntropin, Female, Hormones, Humans, Male, Middle Aged, Prospective Studies, Biomarkers, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.